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Little information is available regarding central nervous system (CNS) relapse of adult leukemia after alloge-
neic hematopoietic stem cell transplantation (HSCT). Therefore, we reviewed the data of 1226 patients with
acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia
(CML) who received first allogeneic HSCT between 1994 and 2004, using the database of the Kanto Study
Group for Cell Therapy (KSGCT), and analyzed the incidence, risk factors, and outcome of patients with
CNS relapse. Twenty-nine patients developed CNS relapse at a median of 296 (9-1677) days after HSCT
with a cumulative incidence of 2.3%. Independent significant factors associated with CNS relapse included
ALL as the underlying diagnosis (relative risk [RR] 5 9.55, 95% confidence interval [CI] 5 1.26-72.2, P 5
.029), nonremission at HSCT (RR5 2.30, 95% CI5 1.03-5.15, P5 .042), the history of CNS invasion before
HSCT (RR5 5.62, 95%CI5 2.62-12.0, P5 9.2 1026), and the prophylactic intrathecal chemotherapy after
HSCT (RR 5 2.57, 95% CI 5 1.21-5.46, P 5 .014). The 3-year overall survival (OS) after CNS relapse was
18%. In 7 of 29 patients with CNS relapse, leukemiawas observed only in CNS. Three of 7 patients were alive
without systemic relapse, resulting in 3-year survival after CNS relapse of 46%. Although the outcome of
patients with CNS relapse was generally poor, long-term disease-free survival could be achieved in some
patients.
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tionINTRODUCTION
Relapse of the original disease remains 1 of the
most important causes of failure after allogeneic hema-
topoietic stem cell transplantation (HSCT) for leuke-
mia. Although majority of the patients develop
systemic relapse, extramedullary relapse has been
also observed after HSCT. The incidence of central00nervous system (CNS) relapse after allogeneic
HSCT ranged from 2.9% to 11% [1-3]. Risk factors
for CNS relapse identified in previous studies included
CNS involvement before HSCT [2] and nonremission
at HSCT [1]. Prophylactic intrathecal administration
of methotrexate (MTX) was shown to decrease the in-
cidence of CNS relapse of acute lymphoblastic leuke-
mia (ALL) in the Seattle study [1], whereas the other 2From the 1Division of Hematology, Saitama Medical Center, Jichi
Medical University, Saitama, Japan; 2Division of Hematology,
Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; 3Di-
vision of Molecular Therapy, The Advanced Clinical Research
Center, The Institute of Medical Science, The University of
Tokyo, Tokyo, Japan; 4Division of Hematology, Department
of Medicine, Keio University School of Medicine, Tokyo,
Japan; 5Department of Hematology, Chiba University School
of Medicine, Chiba, Japan; 6Department of Internal Medicine
and Clinical Immunology, Yokohama City University, Gradu-
ate School of Medicine, Kanagawa, Japan; 7Department of
Internal Medicine, Chiba Aoba Municipal Hospital, Chiba,
Japan; 8Department of Hematology, Yokohama City University
Medical Center, Kanagawa, Japan; 9Department of Medicineand Clinical Science, Gunma University Graduate School of
Medicine, Gunma, Japan; 10Division of Hematology, Shizuoka
Red Cross Hospital, Shizuoka, Japan; 11Division of Hematol-
ogy, Saiseikai Maebashi Hospital, Gunma, Japan; and 12Depart-
ment of Hematology, Kanagawa Cancer Center, Kanagawa,
Japan
Correspondence and reprint requests to: Yoshinobu Kanda, MD,
PhD, Division of Hematology, Saitama Medical Center, Jichi
Medical University, 1-847, Amanuma-cho, Omiya-ku, Sai-
tama-shi, Saitama 330-8503, Japan (e-mail: ycanda-tky@umin.
ac.jp).
Received March 23, 2008; accepted July 2, 2008
1083-8791/08/1410-0001$34.00/0
doi:10.1016/j.bbmt.2008.07.002
Biol Blood Marrow Transplant 14:1100-1107, 2008 1101CNS Relapse after Allogeneic HSCTstudies failed to find the benefit of prophylactic intra-
thecal administration of MTX on CNS relapse in pa-
tients with acute leukemia [2,3]. There has been no
generalized consensus on intrathecal administration
of MTX, and in fact, a survey of the European Group
for Blood and Marrow Transplantation (EBMT) had
reported that the practice varied widely among centers
[4].
We examined the incidence, risk factors, and out-
come of CNS relapse after allogeneic HSCT in adult
patients with acute myelogenous leukemia (AML),
ALL, and chronic myelogenous leukemia (CML),
and also evaluated the prophylactic effect of intrathecal
administration of MTX on CNS relapse.
MATERIALS AND METHODS
Study Population
The study population consisted of 1226 patients,
who underwent allogeneic HSCT for AML, ALL,
and CML for the first time between January 1994
and December 2004 at 10 hospitals participating in
the Kanto Study Group for Cell Therapy (KSGCT).
Transplantation Procedure
Of the 1226 patients, the sources of stem cell was
bone marrow (BM) in 903, peripheral blood stem cells
(PBSC) in 178, BM plus PBSC in 10, and cord blood
(CB) in 134. Conventional myeloablative conditioning
regimens such as total body irradiation (TBI) and cy-
clophosphamide (Cy), busulfan (Bu), and Cy, and their
modified regimens were performed in 1168 patients.
Among them, TBI of at least 10 Gy was performed
in 815 patients. Reduced-intensity conditioning
(RIC) regimens were conducted in 53 patients. Pro-
phylaxis of graft-versus-host disease (GVHD) was at-
tempted with calcineurin inhibitors (cyclosporine
[CsA] or tacrolimus) with or without short-term
MTX in the majority of patients.
Definition of CNS Relapse
CNS relapse was diagnosed as the presence of leu-
kemic cells in the cerebrospinal fluid (CSF). Isolated
CNS relapse was defined as CNS relapse without
any other sites of relapse of leukemia.
Statistical Considerations
Overall survival (OS) was calculated using the Ka-
plan-Meier method. Cumulative incidence of CNS re-
lapse was calculated using Gray’s method, considering
death without CNS relapse as a competing risk [5].
Cumulative incidence of isolated CNS relapse was cal-
culated using Gray’s method, treating systemic relapse
and death without relapse as a competing risk [5]. The
protective effect of chronic GVHD (cGVHD) onCNS relapse was evaluated among patients who devel-
oped bone marrow relapse within 100 days after
HSCT. Factors associated with at least borderline sig-
nificance (P\ .10) in the univariate analyses were sub-
jected to a multivariate analysis using backward
stepwise proportional-hazard modeling. Finally, P
values of\.05 were considered statistically significant.
RESULTS
Characteristics of the Patients
Characteristics of patients included in the study
were listed in Table 1. The median age was 36 years,
ranging from 15 to 69 years. The underlying diseases
were AML (n 5 533), ALL (n 5 352), and CML (n
5 341). Eighty-one patients had the history of CNS
involvement before HSCT. Eight hundred and nine
patients were in complete remission of acute leukemia
or in chronic phase of CML atHSCT, and the remain-
ing patients had active disease. In the following analy-
ses, CML in the chronic phase was included in
leukemia in complete remission.
CNS Relapse
Twenty-nine patients developed CNS relapse at
a median of 296 days (9-1677 days) after HSCT, giving
the cumulative incidence of 2.3% (Figure 1). The me-
dian age was 31 years (range: 17-47). The underlying
disease was ALL in 18, AML in 9, and CML in 2. Six-
teen patients had CNS involvement before HSCT and
Table 1. Characteristics of Patients
Median age (range) at transplantation 36 (15-69)
Sex
Male 762
Female 464
Underlying disease
AML 533
ALL 352
CML 341
Disease status
CR 809
non-CR 416
History of CNS disease
Yes 81
No 802
Type of conditioning
Conventional 1168
Reduced intensity 53
TBI $10 Gy in conditioning
Yes 815
No 404
Donor type
Related 478
Unrelated 548
Stem cell source
BM 902
PBSC 178
BM + PBSC 10
CB 134
CB indicates cord blood.
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CNS relapse was 42% at 1 year and 18% at 3 years
(Figure 2A). OS of the whole patient cohort, patients
with CNS relapse, and those without CNS relapse
was 59.8%, 33.2%, and 60.6%, respectively, at 3 years
after transplantation.
Pretransplant factors that affected the incidence of
CNS relapse after HSCT with at least borderline sig-
nificance were ALL as the underlying disease, active
disease at HSCT, a history of CNS leukemia, the use
of TBI regimens, HSCT from an unrelated donor,
and the use of prophylactic intrathecal chemotherapy
after HSCT (Table 2). Among them, multivariate
analysis showed that ALL as the underlying disease,
active disease at HSCT, the history of CNS involve-
ment, and the use of intrathecal chemotherapy after
HSCT were independently significant (Table 2 and
Figure 3). The cumulative incidences of CNS relapse
in patients with and without a history of CNS involve-
ment before HSCT were 21.3% and 1.3%, respec-
tively (Figure 3A). Patients with ALL were at higher
risk for CNS relapse even in patients in remission at
HSCT without a history of CNS involvement before
HSCT (ALL 2.7%, AML 0.8%, and CML 0.4%, P
5 .088, Figure 4A). Twenty-three patients who had ac-
tive leukemia at HSCT had persistent disease after
HSCT. Among these, only 2 patients developed
CNS relapse after HSCT. However, median survival
of this cohort was only 90 days after HSCT producing
a 1-year survival of 14%, and thus, majority of the pa-
tients died very early, before developing CNS relapse.
Effect of Intrathecal Chemotherapy on the
Incidence of CNS Relapse
The practice of intrathecal chemotherapy in allo-
geneic HSCT recipients varied among the 10 institu-
tions of the KSGCT. Half of them never used
prophylactic intrathecal chemotherapy before and af-
ter HSCT. The remaining half administered intrathe-
cal prophylaxis routinely before HSCT, of which 2
institutions added intrathecal chemotherapy after
days
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Figure 1. Cumulative incidence of CNS relapse treating death without
CNS relapse as competing risk.HSCT for high-risk patients such as those with ALL
or the history of CNS involvement. In this cohort, in-
trathecal prophylaxis before HSCT was conducted in
701 of 887 patients and intrathecal chemotherapy after
HSCTwas done in 141 of 807 patients whose informa-
tion about intrathecal chemotherapy was available.
Antineoplastic agents used for intrathecal chemother-
apymainly consisted ofMTX.Themedian numbers of
intrathecal chemotherapy before and after HSCT
were 1 (range: 1-4) and 2 (range: 1-4), respectively.
We failed to find a significant prophylactic effect of
intrathecal chemotherapy for CNS relapse. The rela-
tive risk for CNS relapse was 1.52 (95% CI 0.61-
3.79, P 5 .37) for intrathecal chemotherapy before
HSCT and 3.92 (95% CI 1.80-8.51, P 5 .00057) for
intrathecal chemotherapy after HSCT (Table 2).
This adverse influence of intrathecal chemotherapy af-
ter HSCT was significant even after adjusted for the
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Figure 2. OS after CNS relapse (A) and that grouped according to iso-
lated CNS relapse or CNS relapse associated with systemic relapse (B).
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Factor Univariate RR (95% CI) P value Multivariate RR (95% CI) P value
Age 1.00 (1.00-1.00) .15
Sex 1.01 (0.65-1.59) .95
Disease CML 1.00 1.00
AML 5.58 (0.70-44.5) .10 3.60 (0.46-28.4) .22
ALL 17.7 (2.36-132.8) .0052 9.55 (1.26-72.2) .029
CR/non-CR 2.33 (1.08-5.04) .031 2.30 (1.03-5.15) .042
History of CNS disease 17.9 (8.30-38.6) 2.0  10213 5.62 (2.62-12.0) 9.2  1026
TBI 2.91 (1.00-8.44) .050
Conventional/reduced intensity
0.99 (0.47-2.07) .97
Related/unrelated 1.85 (1.06-3.23) .030
Source BM 1.00
PBSC 0.24 (0.03-1.77) .16
CB 0.70 (0.17-2.96) .63
Sex mismatch 1.06 (0.42-2.66) .90
HLA mismatch 0.46 (0.06-3.46) .45
Prophylactic IT
before HSCT 1.52 (0.61-3.79) .37
Prophylactic IT
after HSCT 3.92 (1.80-8.51) .00057 2.57 (1.21-5.46) .014
IT indicates intrathecal chemotherapy; CNS, central nervous system; RR, relative risk.underlying disease, disease status at HSCT, and the
history of CNS involvement before HSCT (relative
risk 2.57, 95% CI 1.21-5.46, P 5 .014). Among pa-
tients without a history of CNS involvement before
HSCT who were in remission at HSCT, the inci-
dences of CNS relapse after HSCT were 3.6% and
1.6%who received and did not receive intrathecal che-
motherapy after HSCT, respectively (P 5 .057,
Figure 4B). In patients with a history of CNS involve-
ment before HSCT, the incidences of CNS relapse af-
ter HSCT were 37.4% and 11.6%, respectively, who
received and did not receive intrathecal chemotherapy
after HSCT (P 5 .018; Figure 4C). When we limited
the analysis in patients with ALL, the incidences of
CNS relapse afterHSCTwere 6.2% and 3.7%who re-
ceived and did not receive intrathecal chemotherapy
after HSCT (P5 .17), respectively, in patients without
a history of CNS involvement before HSCTwho were
in remission at HSCT and they were 55.6% and
15.5%, respectively, in patients with a history of
CNS involvement before HSCT (P 5 .0081).
Nine patients developed leukoencephalopathy
with a median onset of 288 days after HSCT. The in-
cidence of leukoencephalopathy was significantly
higher in patients who underwent intrathecal chemo-
therapy after HSCT (3.5% versus 0.5%, P 5 .0076).
Isolated CNS Relapse
Seven patients developed isolated CNS relapse at
a median of 671 days (125-1677 days) after HSCT,
presenting the cumulative incidence of 0.70%. Char-
acteristics of these 7 patients were listed in Table 3.
All received bone marrow as stem cell source. Prog-
nostic factors associated with isolated CNS relapse
with at least borderline significance were age, activedisease at HSCT, CNS involvement before HSCT,
stem cell source, the use of intrathecal chemotherapy
after HSCT, and the absence of HLA mismatch.
Among these, independent significant factors for iso-
lated CNS relapse included the history of CNS in-
volvement before HSCT, the use of PBSC or CB as
stem cell source, and the absence of HLA mismatch
(Table 4). The treatment of isolated CNS relapse con-
sisted of intrathecal chemotherapy and/or cranial irra-
diation and CNS disease was successfully controlled in
5 of the 7 patients. Four patients developed bone mar-
row relapse within 1 year. However, the remaining 3
patients were alive without systemic relapse at 518,
807, and 1149 days after CNS relapse and 1283,
1478, and 2195 days after HSCT, respectively. Sur-
vival after CNS relapse was significantly better in pa-
tients who developed isolated CNS relapse than
those who developed CNS relapse with systemic re-
lapse (46% versus 8% at 3 years, P5 .023, Figure 2B).
Effect of cGVHD on CNS Relapse
Among the 378 patients who experienced bone
marrow relapse within 100 days after HSCT but
were free from CNS relapse at day 100, 21 (6.1%)
showed CNS relapse later on. The incidence of CNS
relapse after bone marrow relapse was 7.1% in patients
with cGVHD and 2.0% in those without cGVHD
(P 5 .14).
Analysis Excluding CML Patients
We repeated these analyses excluding patients with
CML, because the incidence of CNS relapse was ex-
tremely low, as shown in Figure 3C. The cumulative
incidence of CNS relapse was 3.2%. Independently
significant pretransplant factors for CNS relapse
1104 Biol Blood Marrow Transplant 14:1100-1107, 2008K. Oshima et al.were the same as the analyses including CML patients;
ALL compared to AML as the underlying disease (RR
2.68, 95% CI 1.18-6.11, P 5 .019), active disease at
HSCT (RR 2.49, 95%CI 1.08-5.73, P5 .032), the his-
tory of CNS involvement (RR 5.64, 95%CI 2.60-12.3,
P5 .000012), and the use of intrathecal chemotherapy
after HSCT (RR 2.69, 95% CI 1.25-5.81, P 5 .012).
The cumulative incidence of isolated CNS relapse
was 0.9%. Independently significant pretransplant fac-
tors for CNS relapse included ALL compared to AML
as the underlying disease, the history of CNS involve-
ment, the use of PBSC as stem cell source, the absence
of HLA mismatch, and the use of intrathecal chemo-
therapy after HSCT.
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Figure 3. Cumulative incidence of CNS relapse grouped according to
the history of CNS involvement before transplantation (A), disease sta-
tus at transplantation (B), and underlying disease (C).DISCUSSION
The cumulative incidences of CNS relapse and
isolated CNS relapse were 2.3% and 0.70% in this co-
hort, respectively, which were almost comparable with
those in previous studies (Table 5) [1-3]. The history
of CNS leukemia before HSCT was identified as the
strongest predictive factor for CNS relapse after
HSCT in our study as previously reported [1,2].
We could not show a beneficial effect of prophy-
lactic intrathecal chemotherapy on the incidence of
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at transplantation without a history of CNS involvement before trans-
plantation grouped according to the underlying disease (A) and the
use of prophylactic intrathecal chemotherapy (IT) after transplantation
(B). Cumulative incidence of CNS relapse in patient with CNS involve-
ment before transplantation grouped according to the use of prophylac-
tic IT after transplantation (C).
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Patient No. 1 2 3 4 5 6 7
Age 23 31 24 35 26 41 18
Sex M M M M F M M
Disease CML CML ALL AML ALL ALL ALL
Disease status CP2 BC RL2 RL1 RL2 CR1 RL2
History of CNS disease Yes Yes Yes Yes Yes No No
Stem cell source BM BM BM BM BM BM BM
Donor type R R U R R R U
HLA mismatch No Yes No No No No Yes
Conditioning regimem Bu+Cy CA+Cy+TBI ETP+Cy+TBI CA+Cy+TBI ETP+Cy+TBI Cy+TBI CA+Cy+TBI
Days to an isolated CNS
relapse
671 134 125 1565 276 1265 1677
CNS treatment IT+RT IT+RT IT IT+DLI RT IT+RT IT
Systemic relapse No No Yes Yes Yes Yes No
Days from HSCT to
systemic relapse
164 1680 444 1572
Day from CNS relapse to
systemic relapse
39 115 168 307
Outcome Alive Alive Dead Dead Dead Alive Alive
Follow-up duration (days) 1478 1283 236 2031 870 1661 2195
IT indicates intrathecal chemotherapy; RT, radiation; DLI, donor lymphocyte infusion; BU, busulfan; CY, cyclophosphamide; CA, cytarabine; ETP, etopo-
side; CNS, central nervous system; HSCT, hematopoietic stem cell transplantation.CNS relapse after HSCT. The incidence of CNS re-
lapse was rather higher in patients who received intra-
thecal chemotherapy after HSCT. This was probably
biased by the fact that significantly higher proportion
of patients received intrathecal chemotherapy after
HSCT among patients with CNS involvement before
HSCT than those without CNS leukemia (47.4%
versys 13.4%, P\ .0001). However, intrathecal che-
motherapy after HSCT significantly adversely affected
the incidence of CNS relapse even after adjusted for
the underlying disease, disease status at HSCT, and
the history of CNS involvement before HSCT. Also,
a benefit of intrathecal chemotherapy after HSCT
was not shown in patients with ALL, in contrast with
the previous reports [1,6]. This discrepancy might
have resulted from the difference in the intensity ofthe intrathecal chemotherapy. Intrathecal chemother-
apies were administered 6 times after HSCT in the Se-
attle group, whereas the medium number of
intrathecal chemotherapy in the current study was
only 2 (range: 1-4). Therefore, the intensity of intra-
thecal chemotherapy might be important to suffi-
ciently prevent CNS relapse after HSCT. However,
they observed the development of leukoencephalop-
athy in 7 of the 415 patients and we also observed leu-
koencephalopathy significantly more frequently in
patients who received intrathecal chemotherapy after
HSCT than those who did not. Therefore, such an in-
tensive intrathecal chemotherapy should be avoided
for patients at low risk for CNS relapse.We had a con-
cern that the use of intrathecal chemotherapy after
HSCT might delay immune recovery and therebyTable 4. Impact of Pretransplant Factors on the Incidence of Isolated CNS Relapse after Transplantation
Factor Univariate RR (95% CI) P-Value Multivariate RR (95% CI) P-Value
Age 0.99 (0.98-1.00) .055
Sex 1.05 (0.47-2.34) .90
Disease CML 1.00
AML 0.73 (0.04-11.9) .82
ALL 5.31 (0.61-45.9) .13
CR/non-CR 4.98 (0.97-25.7) .055
History of CNS disease 48.3 (9.37-249.4) 3.6  1026 48.1 (9.40-245.9) 3.3  1026
TBI 3.21 (0.38-26.8) .28
Conventional/reduced intensity
1.08 (0.26-4.49) .92
Related/unrelated 1.45 (0.65-3.24) .37
Source BM 1.00 1.00
PBSC N.A. <.0001 N.A. <.0001
CB N.A. <.0001 N.A. <.0001
Sex mismatch 1.58 (0.26-9.41) .62
HLA mismatch N.A. <.0001 N.A. <.0001
Prophylactic IT before
HSCT 1.09 (0.21-5.61) 0.92
Prophylactic IT after HSCT 7.11 (1.62-31.2) 0.0094
N.A. indicates not assessable because no events were observed in the group; IT, intrathecal chemotherapy; RR, relative risk.
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n
Underlying Disease
(AML/ALL/CML)
History of CNS
Leukemia (%)
CR at Transplant
(%)
Allogeneic
Transplant (%)
Incidence of
CNS Relapse (%) Reference
1 415 217/198/0 23.4 47.7 100 2 in AML, 13 in ALL 1
2 92 0/92/0 22.8 100 71.7 11 2
3 487 366/121*/0 3.5 100 67.6 2.9 3
4 1226 533/352/341 9.2 65.8 100 2.3 Present report
*Including 5 patients with acute unclassified leukemia.increase the risk of systemic relapse, but the incidence
of systemic relapse was not significantly different be-
tween those who received intrathecal chemotherapy
and those who did not (relative risk 1.11, 95% CI
0.79-1.55, P 5 .56). The use of total body irradiation
(TBI) in the conditioning regimen has been considered
to prevent CNS relapse, because irradiation is effective
for so called sanctuary sites of chemotherapy. How-
ever, the incidence of CNS relapse was also rather
higher in patients who received the TBI regimen.
This may be again because of the fact that significantly
higher proportion of patients received the TBI regi-
men among patients with CNS involvement before
HSCT than those without CNS leukemia (81.5% ver-
sus 57.9%, P\ .0001).
As for stem cell source, isolated CNS relapse was
observed exclusively after BMT. A possible explana-
tion for this may be the year effect, because allogeneic
PBSCT and CBT started after 2000 in Japan. How-
ever, the year of HSCT of patients who developed iso-
lated CNS relapse evenly ranged between 1997 and
2002. Another possible explanation is the presence of
graft-versus-CNS relapse effect enhanced by increased
incidence of cGVHD after allogeneic PBSCT and the
presence of HLA-mismatch in CBT. The significantly
higher incidence of CNS relapse after autologous
HSCT than that after allogeneic HSCT suggested
the existence of such an immunologicprotection
against CNS relapse [2]. Isolated extramedullary re-
lapse was also reported to be observed earlier in autol-
ogous HSCT than in allogeneic HSCT [7].
Furthermore, successful treatment of CNS relapse
with reduced-intensity transplantation may suggest
the presence of graft-versus-leukemia CNS leukemia
effect [8], although the other reports doubted such ef-
fect against for CNS lesions [9-12]. The observed ten-
dency toward a lower CNS relapse incidence after
bone marrow relapse in patients with cGVHD than
those without cGVHD in the current studymight sup-
port this speculation, although we have no immuno-
logic evidence.
The prognosis of patients who developed relapse
after allogeneic HSCT has been reported to be ex-
tremely poor [13,14]. Also, survival after isolated
CNS relapse was reported to be no better than that af-
ter bone marrow relapse in pediatric patients with
AML and adult patients with ALL [15,16]. However,in the current study, 3 of the 7 patients who developed
isolated CNS relapse were alive for more than a year
without leukemia, resulting in the significantly better
survival than those who developed CNS relapse after
or simultaneously with systemic relapse. We could
not identify the reason for this discrepancy, but the
age and underlying disease of the study population dif-
fered between our study and the previous report. We
consider that an intensive treatment against CNS leu-
kemia is warranted for adult patients with isolated
CNS relapse.
In conclusion, we confirmed that ALL as the un-
derlying disease, active disease at HSCT, and the his-
tory of CNS involvement before HSCT were
significant predictors for CNS relapse after HSCT.
We failed to show a significant prophylactic effect of
intrathecal chemotherapy to prevent CNS relapse
and such a prophylactic treatment should be avoided
for patients at low risk for CNS relapse. The prognosis
for isolated CNS relapse was surprisingly good.
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